

ESMO 2024 Industry Satellite Symposium

Evolving Patient-Centered Therapies for Metastatic NSCLC



Saturday, 14 September 2024 | 13:00 – 14:30 CEST

Burgos Auditorium, Hall 5, Fira Barcelona Gran Via, Barcelona, Spain



Meeting Chair
Jarushka Naidoo, MBBCh, MHS
Beaumont RCSI Cancer Centre
Dublin, Ireland



Faculty
Terri Conneran
KRAS Kickers
Charlotte, North Carolina, United States



Faculty
Luis Paz-Ares, MD, PhD
Hospital Universitario 12 de Octubre
Madrid, Spain



Faculty
Alexander Drilon, MD
Memorial Sloan Kettering Cancer Center
New York, New York, United States

13:00 – 13:05
(5 minutes)

Welcome and Introductions

Jarushka Naidoo, MBBCh, MHS

13:05 – 13:13
(8 minutes)

The Importance of Patient Empowerment During Their Journey

Terri Conneran

13:13 – 13:28
(15 minutes)

PD-L1 <1% in Metastatic NSCLC: Guiding Treatment Decisions for Potential Durable Outcomes in a Patient Population With Unmet Needs

Luis Paz-Ares, MD, PhD

13:28 – 13:43
(15 minutes)

Kicking Off Targeted Medicine for Patients With KRAS G12C–Mutated Metastatic NSCLC

Jarushka Naidoo, MBBCh, MHS

13:43 – 13:58
(15 minutes)

Next-Generation Tyrosine Kinase Inhibitors: The Evolving Treatment Landscape of Cancers With ROS1 or NTRK Fusions

Alexander Drilon, MD

13:58 – 14:28
(30 minutes)

Panel Discussion: What Would Be Your Treatment Decision?

All faculty

14:28 – 14:30
(2 minutes)

Closing Remarks

Jarushka Naidoo, MBBCh, MHS

This Industry-Sponsored Symposium Is a Medical Education Activity That Is Organized and Funded by the Medical Department of Bristol Myers Squibb.